Genentech Roferon-A promotion to inaugurate oncology marketing; Roche continues to promote for hepatitis C.
Executive Summary
GENENTECH ROFERON-A PROMOTION TO INAUGURATE ONCOLOGY MARKETING for the company, which has agreed to promote Roche's Roferon-A (recombinant interferon alfa-2a) for its oncology indications of hairy-cell leukemia, AIDS-related Kaposi's sarcoma and Philadelphia chromosome-positive chronic myelogenous leukemia.